On the other hand, suppressing GNAS expression by CRISPR knockout of GNAS in BRAFV600E CRC cell lines (GNAS-KO) prevented SFK activation after vemurafenib treatment (Fig. 5g). The gene discussed is GNAS; the disease is colorectal carcinoma.